FDA approves Xywav to treat excessive daytime sleepiness in rare disorder

Federal regulators have approved a new treatment for idiopathic hypersomnia. The drug, Xywav, aims to reduce excessive daytime sleepiness in patients with the condition. It has already been used for other sleep disorders. Xywav is an oral medication containing calcium, magnesium, potassium, and sodium oxybate. Clinical trials proved its effectiveness in cutting daytime sleepiness for those with idiopathic hypersomnia. However, it carries a black box warning for central nervous system depression, abuse, and misuse.

Common side effects include nausea, headache, dizziness, anxiety, and vomiting. The drug’s approval follows its prior use in treating different sleep-related conditions.

Sleep issues remain widespread in the US. One in three people report not getting enough rest. Factors like anxiety, depression, and iron deficiency anaemia can contribute to daytime fatigue. Experts recommend keeping electronics away from the bed, adopting restful routines, and leading a healthy lifestyle to improve sleep quality. Xywav now offers a new option for patients with idiopathic hypersomnia. Its approval expands the range of treatments for excessive sleepiness. Doctors will need to monitor its use due to the potential risks and side effects.